Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page % o* j! g, J$ k9 M9 h! U9 [
* D) @- J! p5 @1 Y) C! D
/ t- u; o* J" t% PSub-category:- i! D8 Z/ o5 H4 a3 U& D5 ^
Molecular Targets
7 V! g8 w% J0 i/ F$ Q0 F+ _6 K1 f8 C& F+ W: P# R8 D( ^( f( L
0 S3 C' w2 @9 w5 _- P! ECategory:
1 o- T4 P& e, ]+ _. S2 M! XTumor Biology . S# t$ S* c. `" W) p# J" t
4 K& V7 V1 i" K/ I/ G7 s. }! z) j
Meeting:* N& @. W. y' O4 r0 W$ R+ Z
2011 ASCO Annual Meeting
- E2 M. U- `; r6 P A a& t
+ D# `; m4 i Y5 T8 ~2 p+ W1 N4 Q$ [3 X) m X7 b3 |
Session Type and Session Title:
, U& a" p1 ]" a) U* hPoster Discussion Session, Tumor Biology
' b9 m+ r% K5 X% y) N7 ~% o
0 Q3 A$ ~3 t8 Z, q7 j( e
4 {$ _ ~$ M$ O- b* \; LAbstract No:! Z, B' l1 t) L5 K5 m
10517 , J8 m7 p5 f% k8 q
8 z( q' a: N, A, ~
( y o: P' ~1 U' @) J; r4 x$ M2 j+ M+ i
Citation:% ~; i# t) p# W7 ?2 ]; n
J Clin Oncol 29: 2011 (suppl; abstr 10517) 1 k8 B S1 J2 o) Y" g9 u
6 ]3 @6 w; Q+ v' [9 G
5 `9 L J' _2 B( m* m$ w( C, R7 v7 N- EAuthor(s):
% ^4 E1 q$ w( @6 eJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
, `0 {1 `4 N7 X) I" b
2 E& J5 m! |* H' q" H2 z5 Z) K* a0 S! x/ r$ r# m
+ S/ q3 ]. N( b z( d
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.1 _0 T; ]" R, m
& E8 c5 v% _: E1 h+ f- |/ l2 HAbstract Disclosures' J/ N# W) Q( L& p
/ ^6 }5 P4 x4 ]8 lAbstract:
5 ]5 F- O1 M7 y! {5 p" O9 q3 p7 e) L% h0 u7 g3 c6 b( c
, |6 f [+ Y! X. Y( X
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation./ r, [: a, Q( o2 b' N; [/ A
7 d5 ^' X( l8 h6 h/ [. C
" p! o9 k, _. e4 N5 V" i |